ClinicalTrials.gg
CompletedNCT05605262Updated Nov 4, 2022

Effects of 100% Medical Grade Manuka Honey on Tympanic Membrane Reconstruction Healing.

A Phase 2/3 interventional study of Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey in Otitis Media, Suppurative and Tympanic Membrane Perforation, sponsored by Fakultas Kedokteran Universitas Indonesia. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-11-04.

Sponsored by Fakultas Kedokteran Universitas Indonesia · Phase 2/3, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 1 month ago, and no results have been posted to the registry.
  • Registered 1 year 4 months after the study started (first participant enrolled Jun 2021, registered Oct 2022).
Phase
Phase 2/3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Throughout history, honey has been recognized for its healing properties. The use of honey for its medicinal properties dates back to 2200 BCE.

The purpose of this clinical trial is to learn about the healing effects of 100% medical grade Manuka honey in participants with Chronic Suppurative Otitis Media of the mucosal type.

The main question it aims to answer is: Can 100% Manuka honey given at the time of Tympanoplasty improve the re-epithelialization (healing process) of the tympanic membrane compared to controls?

Participants in the intervention group will receive a wound dressing of 100% medical grade Manuka honey after reconstructive surgery of the tympanic membrane.

Researchers will compare the intervention group to the control group to see healing process.

Read the detailed description

The aim of the present study is to conduct a randomized clinical trial to compare the effect of 100% sterile Manuka honey on re-epithelialization of the tympanic membrane post Tympanoplasty compared to the control group. The investigation will involve 64 participants with Chronic Suppurative Otitis Media of the mucosal type, who will be randomly put into two groups (intervention or control), where the intervention group will receive a dressing of 100% sterile Manuka honey during surgery. Results of this study will inform practitioners as to the potential benefits of 100% sterile Manuka honey on the re-epithelialization of the tympanic membrane.

02

Conditions studied

  • Otitis Media, Suppurative
  • Tympanic Membrane Perforation

Keywords

  • Chronic Suppurative Otitis Media
  • Manuka Honey
  • Wound Healing
  • Re-epithelialization
  • Tympanoplasty
  • Tympanic Membrane
03

In context

Tympanic Membrane Perforation

53 studies on the registry are indexed under Tympanic Membrane Perforation; 14 are open to participants now.

This study's enrollment of 64 is above the median of 57 across 39 interventional studies indexed under Tympanic Membrane Perforation.

Browse Tympanic Membrane Perforation studies →

Lead sponsor

Fakultas Kedokteran Universitas Indonesia is the lead sponsor of 36 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants of 18 - 45 years of age.
  • Participants with Chronic Suppurative Otitis Media of the mucosal type.
  • Provision of signed and dated form. Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Participants who previously received surgical therapy for Chronic Suppurative Otitis Media or have recurrent or residual disease.
  • Participants with anatomical pathology results showing and/or suspecting a tumor.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Intervention

    Manukamed - 100% sterile manuka honey

    Drug: Manukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey

  • No intervention
    Control

    No intervention was given. Participants receive standard wound care of the tympanic membrane which includes 0.3% Ofloxacin otic ear drops which were used twice a day for 5 days.

Interventions

  • DrugManukamed - Manukapli 100% sterile honey wound dressing - Premium medical grade 16+ Leptospermum Scoparium New Zealand honey

    After surgical reconstruction of the tympanic membrane by grafting, Manukamed - Manukapli 100% Sterile honey wound dressing is applied onto the gelfoam to close the area, followed by an antibiotic tampon.

    Also known as: Manukamed - Manukapli 100% sterile honey wound dressing

06

What researchers measure

Primary outcomes

  1. Weekly Evaluation of Tympanic Membrane Re-epithelialization Post-tympanoplasty

    Epithelialization of the tympanic membrane was measured using an indicator tool utilizing a filter paper (5 mm in width and 10 mm in length) with a water-based ink on one end as the indicator. Exposure of the indicator to the exudate on the surface of the tympanic membrane will reveal the status of the wound (wet/ dry).

    Time frame: 2 weeks (14 days following surgery)

Secondary outcomes

  1. Weekly Evaluation of Tympanic Membrane Re-epithelialization Post-tympanoplasty

    Epithelialization of the tympanic membrane was measured using an indicator tool utilizing a filter paper (5 mm in width and 10 mm in length) with a water-based ink on one end as the indicator. Exposure of the indicator to the exudate on the surface of the tympanic membrane will reveal the status of the wound (wet/ dry).

    Time frame: 3 weeks (21 days following surgery)

  2. Weekly Evaluation of Tympanic Membrane Re-epithelialization Post-tympanoplasty

    Epithelialization of the tympanic membrane was measured using an indicator tool utilizing a filter paper (5 mm in width and 10 mm in length) with a water-based ink on one end as the indicator. Exposure of the indicator to the exudate on the surface of the tympanic membrane will reveal the status of the wound (wet/ dry).

    Time frame: 4 weeks (28 days following surgery)

  3. Weekly Evaluation of Tympanic Membrane Re-epithelialization Post-tympanoplasty

    Epithelialization of the tympanic membrane was measured using an indicator tool utilizing a filter paper (5 mm in width and 10 mm in length) with a water-based ink on one end as the indicator. Exposure of the indicator to the exudate on the surface of the tympanic membrane will reveal the status of the wound (wet/ dry).

    Time frame: 5 weeks (35 days following surgery)

  4. Weekly Evaluation of Tympanic Membrane Re-epithelialization Post-tympanoplasty

    Epithelialization of the tympanic membrane was measured using an indicator tool utilizing a filter paper (5 mm in width and 10 mm in length) with a water-based ink on one end as the indicator. Exposure of the indicator to the exudate on the surface of the tympanic membrane will reveal the status of the wound (wet/ dry).

    Time frame: 6 weeks (42 days following surgery)

  5. Evaluation of Ototoxicity

    Hearing function will be evaluated by conducting a Brain Evoked Response Audiometry exam. If the BERA results show decreased stimulus of more than 10 decibels, treatment for sudden deafness is started immediately.

    Time frame: 5 weeks (35 days following surgery)

07

Study locations

1 site
  • Faculty of Medicine - University of Indonesia
    Jakarta, DKI Jakarta 10430, Indonesia
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — If requested, data records without identifying patient information can be shared

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Sep 2022, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2022
First posted
Nov 4, 2022
StartActual
Jun 13, 2021
Primary completionActual
Sep 29, 2022
CompletionActual
Sep 29, 2022
Last update
Nov 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05605262
Lead sponsor
Fakultas Kedokteran Universitas Indonesia
Responsible party
Sponsor
First posted
Nov 4, 2022
Start date
Jun 13, 2021
Primary completion
Sep 29, 2022
Completion
Sep 29, 2022
Last update
Nov 4, 2022

Study contacts

Harim Priyono
principal investigator · Faculty of Medicine, University of Indonesia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion